CYTO logo

Altamira Therapeutics (CYTO) Cash From Operations

Annual CFO

-$614.50 K
+$8.75 M+93.44%

December 1, 2023

Summary

Performance

1-Year Change

+93.44%

3-Year Change

+88.92%

5-Year Change

+95.43%

15-Year Change

+97.53%

CYTO Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

76%
CYTO annual cash flow from operations is higher than 76% of companies in Healthcare sector

High & Low

All-time High

-$614.50 K
CYTO annual cash flow from operations is currently at an all-time high

3-Year Low

-$14.96 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
CYTO previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
CYTO next annual earnings announcement has not yet been scheduled

OtherCYTOcash flowmetrics:

Annual CFI

$2500.00
CYTO annual cash flow from investing activities is $2500.00

Annual CFF

$1.19 M
CYTO annual cash flow from financing activities is $1.19 million

Annual FCF

-$614.50 K
CYTO annual free cash flow is -$614.50 thousand

Annual CAPEX

-
CYTO annual capital expenditures value is unknown

Quarterly CFO

N/A

June 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CYTO Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.59 M
CYTO quarterly cash flow from operations is currently at an all-time high

3-Year Low

-
CYTO quarterly cash flow from operations 3-year low is unknown

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
CYTO previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
CYTO next earnings announcement has not yet been scheduled

OtherCYTOcash flowmetrics:

Quarterly CFI

-
CYTO quarterly cash flow from investing activities value is unknown

Quarterly CFF

-
CYTO quarterly cash flow from financing activities value is unknown

Quarterly FCF

-
CYTO quarterly free cash flow value is unknown

Quarterly CAPEX

-
CYTO quarterly capital expenditures value is unknown

TTM CFO

N/A

June 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CYTO TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.59 M
CYTO TTM cash flow from operations is currently at an all-time high

3-Year Low

-
CYTO TTM cash flow from operations 3-year low is unknown

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
CYTO previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
CYTO next earnings announcement has not yet been scheduled

OtherCYTOcash flowmetrics:

TTM CFI

-
CYTO TTM cash flow from investing activities value is unknown

TTM CFF

-
CYTO TTM cash flow from financing activities value is unknown

TTM FCF

-
CYTO TTM free cash flow value is unknown

TTM CAPEX

-
CYTO TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

CYTO Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+93.4%--
3 y3 years+88.9%--
5 y5 years+95.4%--

CYTO Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+95.9%
5 y5-yearat high+95.9%
alltimeall timeat high+97.9%

Altamira Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2023
-$614.50 K(-93.4%)
-
-
Dec 2022
-$9.37 M(-37.4%)
-
-
Dec 2021
-$14.96 M(+169.8%)
-
-
Dec 2020
-$5.54 M(-36.0%)
-
-
Dec 2019
-$8.66 M(-35.5%)
-
-
Dec 2018
-$13.44 M(-46.1%)
-$1.92 M(-54.4%)
-$13.44 M(-25.9%)
Sep 2018
-
-$4.22 M(+102.9%)
-$18.15 M(-2.2%)
Jun 2018
-
-$2.08 M(-60.2%)
-$18.55 M(-20.6%)
Mar 2018
-
-$5.22 M(-21.2%)
-$23.37 M(-6.2%)
Dec 2017
-$24.92 M(-13.8%)
-$6.63 M(+43.6%)
-$24.92 M(+7.6%)
Sep 2017
-
-$4.62 M(-33.1%)
-$23.15 M(-10.3%)
Jun 2017
-
-$6.90 M(+1.9%)
-$25.80 M(-8.2%)
Mar 2017
-
-$6.77 M(+39.3%)
-$28.10 M(-2.8%)
Dec 2016
-$28.91 M
-$4.86 M(-33.1%)
-$28.91 M(-4.4%)
Sep 2016
-
-$7.27 M(-21.0%)
-$30.23 M(+0.3%)
DateAnnualQuarterlyTTM
Jun 2016
-
-$9.20 M(+21.3%)
-$30.14 M(+0.1%)
Mar 2016
-
-$7.58 M(+22.6%)
-$30.10 M(+3.6%)
Dec 2015
-$29.06 M(+48.8%)
-$6.19 M(-13.7%)
-$29.06 M(+6.4%)
Sep 2015
-
-$7.17 M(-21.8%)
-$27.31 M(+22.8%)
Jun 2015
-
-$9.16 M(+40.0%)
-$22.24 M(+3.4%)
Mar 2015
-
-$6.55 M(+47.7%)
-$21.50 M(+10.1%)
Dec 2014
-$19.53 M(+23.4%)
-$4.43 M(+111.1%)
-$19.53 M(-3.0%)
Sep 2014
-
-$2.10 M(-75.1%)
-$20.13 M(-11.6%)
Jun 2014
-
-$8.42 M(+83.9%)
-$22.78 M(+21.1%)
Mar 2014
-
-$4.58 M(-8.9%)
-$18.82 M(+18.9%)
Dec 2013
-$15.82 M(+221.1%)
-$5.03 M(+5.9%)
-$15.82 M(+46.6%)
Sep 2013
-
-$4.75 M(+6.5%)
-$10.80 M(+78.5%)
Jun 2013
-
-$4.46 M(+180.7%)
-$6.05 M(+280.7%)
Mar 2013
-
-$1.59 M
-$1.59 M
Dec 2012
-$4.93 M
-
-

FAQ

  • What is Altamira Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Altamira Therapeutics?
  • What is Altamira Therapeutics annual CFO year-on-year change?
  • What is the all time high quarterly CFO for Altamira Therapeutics?
  • What is the all time high TTM CFO for Altamira Therapeutics?

What is Altamira Therapeutics annual cash flow from operations?

The current annual CFO of CYTO is -$614.50 K

What is the all time high annual CFO for Altamira Therapeutics?

Altamira Therapeutics all-time high annual cash flow from operations is -$614.50 K

What is Altamira Therapeutics annual CFO year-on-year change?

Over the past year, CYTO annual cash flow from operations has changed by +$8.75 M (+93.44%)

What is the all time high quarterly CFO for Altamira Therapeutics?

Altamira Therapeutics all-time high quarterly cash flow from operations is -$1.59 M

What is the all time high TTM CFO for Altamira Therapeutics?

Altamira Therapeutics all-time high TTM cash flow from operations is -$1.59 M